Adrian Liam Gill

USPTO Granted Patents = 15 (Patent Applications = 3)

CIPO Patents = 4

EPO Patents = 5 (Patent Applications = 1)

Average Co-Inventor Count = 8.8

ph-index = 6

Forward Citations = 168(Granted Patents)

Location History:

Caldecote, GB (2008)
Cambridge, GB (2011)
Macclesfield, GB (2009 - 2014)
Buxton, GB (2012 - 2014)
Cheshire, GB (2010 - 2015)

Company Filing History:

14 out of 123

Astex Therapeutics Limited

patents

2 out of 263

Cancer Research Technology Limited

patents

2 out of 51

The Institute of Cancer Research: Royal Cancer Hospital

patents

4. 1 out of 3

The Wellcome Trust Limited

patents

where one patent can have more than one assignee

Years Active: 2008-2015

Loading Chart...

15 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9051278 - 3,4-disubstituted 1H-pyrazole compounds and their use as cyclin dependent kinase and glycogen synthase kinase-3 modulators (2015-06-09),

2. 8895745 - Bicyclic heterocyclic compounds as FGFR inhibitors (2014-11-25),

3. 8779147 - 3,4-disubstituted 1H-pyrazole compounds and their use as cyclin dependent kinase and glycogen synthase kinase-3 modulators (2014-07-15),

4. 8778936 - Pyrazole compounds that modulate the activity of CDK, GSK and aurora kinases (2014-07-15),

5. 8513276 - Imidazo[1,2-a]pyridine compounds for use in treating cancer (2013-08-20),

6. 8399442 - Pharmaceutical compounds (2013-03-19),

7. 8131527 - FGFR pharmacophore compounds (2012-03-06),

8. 8110573 - Pyrazole compounds that modulate the activity of CDK, GSK and aurora kinases (2012-02-07),

9. 8080666 - 3,4-disubstituted 1H-pyrazole compounds and their use as cyclin dependent kinase and glycogen synthase kinase-3 modulators (2011-12-20),

10. 7977477 - Benzimidazole derivatives and their use as protein kinase inhibitors (2011-07-12),

11. 7825140 - 3,4-disubstituted 1H-pyrazole compounds and their use as cyclin dependent kinase and glycogen synthase kinase-3 modulators (2010-11-02),

12. 7745638 - 3,4-disubstituted 1H-pyrazole compounds and their use as cyclin dependent kinase and glycogen synthase kinase-3 modulators (2010-06-29),

13. 7737152 - 6-carboaryl-oxy-pyrazin-2-yl-carboaryl-amines and compositions comprising said compounds (2010-06-15),

14. 7625922 - Imidazo[4,5-b]pyridin-2-one and oxazolo[4,5-b]pyridin-2-one compounds and analogs thereof as therapeutic compounds (2009-12-01),

15. 7385059 - 3,4-disubstituted 1H-pyrazole compounds and their use as cyclin dependent kinase and glycogen synthase kinase-3 modulators (2008-06-10),

Title: The Innovations of Adrian Liam Gill

Introduction: Adrian Liam Gill is an esteemed inventor based in Cheshire, Great Britain, known for his significant contributions to the field of pharmaceuticals. With a remarkable portfolio of 15 patents, Gill's work primarily focuses on the development of compounds that address critical medical conditions, particularly cancers.

Latest Patents: One of Adrian Liam Gill's latest patents is for 3,4-disubstituted 1H-pyrazole compounds, which serve as modulators for cyclin-dependent kinase and glycogen synthase kinase-3. This invention provides innovative compounds designed for the prophylaxis and treatment of disease states, especially cancers that are mediated by these crucial kinases. Another recent patent revolves around bicyclic heterocyclic compounds identified as FGFR inhibitors, which include new derivatives for pharmaceutical compositions aimed at treating various diseases, including cancer.

Career Highlights: Throughout his career, Adrian has made notable strides while working with respected organizations. His tenure at Astex Therapeutics Limited and Cancer Research Technology Limited highlights his commitment and expertise in drug discovery and development. These positions have allowed him to refine his skills and contribute to groundbreaking advancements in the pharmaceutical industry.

Collaborations: In his innovative journey, Adrian has collaborated with prominent figures such as Valerio Berdini and Maria Grazia Carr. These partnerships have fostered a collaborative environment that emphasizes the importance of teamwork in achieving significant technological advancements.

Conclusion: Adrian Liam Gill's contributions to the field of pharmaceuticals through his patents are pivotal in the fight against cancer and other diseases. His dedication and innovative spirit continue to inspire future generations of inventors and researchers in the pursuit of advancing medical science.

This text is generated by artificial intelligence and may not be accurate.